Guideline recommended evidence-based clinical care correlates with improved patient outcomes. In real life care, however, adherence to guideline recommendations remains suboptimal. In real life, patients may receive suboptimal treatment and as a result treatment targets are not always met. To support and improve secondary prevention for cardiovascular disease, PENELOPE and PENELOPE-CTRL are designed to support guideline implementation on lipid management and provide valuable feedback to care-givers on real world data.
The recent PENELOPE study was designed to determine the effect of a protocolized, Dutch-, and ESC- guideline based strategy of stepwise intensified lipid management in patients at very high risk for ACS. In PENELOPE 22 Dutch non-academic hospitals, members of the WCN investigator network, implemented a protocol guided guideline approach in a consecutive cohort of very high-risk patients admitted for ACS over the period 01-01-2019 to 31-08-2020. Lipid values and medication strategy are collected at baseline (index ACS), and after three months and one year post ACS, in order to establish the percentage of patients on target (LDL). The current PENELOPE-CTRL study on the other hand, is designed to serve as a contemporary control cohort for PENELOPE. PENELOPE-CTRL is a retrospective observational study, creating a contemporary snapshot of real-life lipid management for secondary prevention in very high-risk patients. PENELOPE-CTRL will collect data in similar hospitals who did not participate in the PENELOPE trial. To allow comparison of these two strategies, protocol guided versus real life implementation of the cholesterol treatment guidelines, both cohorts include similar patients, and similar data will be collected (e.g., lipid lowering drugs, lipid panels) . Analysis will be done at similar time points. Comparing the real-life data from PENELOPE-CTRL with the data from the PENELOPE study will quantify the effect of a strategy of protocolized guideline-based lipid management with regards to the incidence of target LDL-C levels in very high-risk patients, 3 months and one year after hospitalisation with a myocardial infarction.
Study Type
OBSERVATIONAL
Enrollment
827
NoordWest Hospital (NWZ)
Alkmaar, Netherlands
Reinier de Graaf Hospital
Delft, Netherlands
Deventer Hospital
Deventer, Netherlands
Treant Hospital
Emmen, Netherlands
Saxenburg Medisch Centrum
Hardenberg, Netherlands
Elkerliek Hospital
Helmond, Netherlands
Alrijne Hospital
Leiden, Netherlands
Isala Hospital
Meppel, Netherlands
Canisius Wilhemina Hospital (CWZ)
Nijmegen, Netherlands
Haaglanden Hospital
The Hague, Netherlands
...and 3 more locations
Number of patients reaching the LDL-C target level (≤ 1.8 mmol/L)
reaching LDL-C target level (≤ 1.8 mmol/L) 3 months after admission for a type I (N)STEMI, compared to the designated PENELOPE cohort
Time frame: 3 months
Incidence of LDL-C target level (≤ 1.8 mmol/L)
Incidence of LDL-C (≤ 1.8 mmol/L) at baseline (admission for a type I (N)STEMI), 3 months and 1 year after baseline, compared to the designated PENELOPE cohort.
Time frame: 1 year
Incidence of LDL-C target level (≤ 1.4 mmol/L)
Incidence of LDL-C (≤ 1.4 mmol/L) at baseline (admission for a type I (N)STEMI), 3 months and 1 year after baseline, compared to the designated PENELOPE cohort.
Time frame: 1 year
incidence of achieving 50% LDL-C reduction
Incidence of achieving 50% LDL-C reduction compared to baseline, after 3 months and 1 year, also adjusted to the start date of the related drug regimen.
Time frame: 1 year
LLT compared to PENELOPE cohort
Lipid lowering therapy at baseline, after 3 months and 1 year, compared to the designated PENELOPE cohort.
Time frame: 1 year
LDL-C level 3 months after adjustment
LDL-C level at 3 months, also adjusted to the start date of the related drug regimen.
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.